RxDoctor Payments Data

John Jordan, APRN

Family · Norman, OKNPI 1548733249

Payments from drug & device makers

$1,580in general payments, 2019–2025

Across 56 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Welch Allyn$380
  • AstraZeneca$196
  • Pfizer$164
  • AbbVie$162
  • GSK$149
  • Shield Therapeutics Inc$125
  • plus $403 from 8 others

What the payments were for

  • Food & beverage$1,20076%
  • Other$38024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,580 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$20,874
Medicare patients
109
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$41,031
EliquisApixaban61$36,519
Spiriva RespimatTiotropium Bromide53$27,438
MounjaroTirzepatide21$23,601
JardianceEmpagliflozin20$11,535
Atorvastatin Calcium285$2,744
Novolog FlexpenInsulin Aspart15$2,653
SynthroidLevothyroxine Sodium107$2,498
Wixela InhubFluticasone Propion/Salmeterol18$1,931
Ultra-Fine Short Pen NeedlePen Needle, Diabetic28$1,810
AlogliptinAlogliptin Benzoate12$1,696
Albuterol Sulfate HfaAlbuterol Sulfate50$1,393
Fluticasone Propionate82$1,169
Fenofibrate84$966
Omeprazole99$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$41,03145 claims
PfizerEliquis$164$36,51961 claims
Lilly USA, LLCMounjaro$99$23,60121 claims
AbbVieSynthroid$162$2,498107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →